Lataa...
Characterizing expanded access and compassionate use programs for experimental drugs
OBJECTIVE: We sought to determine the characteristics of “expanded access” and “compassionate use” programs registered in ClinicalTrials.gov and to determine the percentage of drugs provided through these programs that ultimately received FDA marketing approval. RESULTS: We identified 398 expanded a...
Tallennettuna:
| Julkaisussa: | BMC Res Notes |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5534121/ https://ncbi.nlm.nih.gov/pubmed/28754150 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13104-017-2687-5 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|